399 related articles for article (PubMed ID: 35422075)
21. Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients.
Souan L; Abdel-Razeq H; Al Zughbieh M; Al Badr S; Sughayer MA
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515127
[TBL] [Abstract][Full Text] [Related]
22. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
23. Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
Uwamino Y; Kurafuji T; Takato K; Sakai A; Tanabe A; Noguchi M; Yatabe Y; Arai T; Ohno A; Tomita Y; Shibata A; Yokota H; Yamasawa W; Namkoong H; Sato Y; Hasegawa N; Wakui M; Murata M;
Vaccine; 2022 Jul; 40(32):4538-4543. PubMed ID: 35718591
[TBL] [Abstract][Full Text] [Related]
24. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
25. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination.
Appelman B; van der Straten K; Lavell AHA; Schinkel M; Slim MA; Poniman M; Burger JA; Oomen M; Tejjani K; Vlaar APJ; Wiersinga WJ; Smulders YM; van Vught LA; Sanders RW; van Gils MJ; Bomers MK; Sikkens JJ;
EBioMedicine; 2021 Oct; 72():103589. PubMed ID: 34571363
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
27. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
[TBL] [Abstract][Full Text] [Related]
28. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
Yang LM; Costales C; Ramanathan M; Bulterys PL; Murugesan K; Schroers-Martin J; Alizadeh AA; Boyd SD; Brown JM; Nadeau KC; Nadimpalli SS; Wang AX; Busque S; Pinsky BA; Banaei N
J Clin Virol; 2022 Aug; 153():105217. PubMed ID: 35714462
[TBL] [Abstract][Full Text] [Related]
29. Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
Giannoccaro MP; Vacchiano V; Leone M; Camilli F; Zenesini C; Panzera I; Balboni A; Tappatà M; Borghi A; Salvi F; Lugaresi A; Rinaldi R; Di Felice G; Lodi V; Lazzarotto T; Liguori R;
J Neurol; 2022 Aug; 269(8):4000-4012. PubMed ID: 35503375
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
31. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients.
Sattler A; Schrezenmeier E; Weber UA; Potekhin A; Bachmann F; Straub-Hohenbleicher H; Budde K; Storz E; Proß V; Bergmann Y; Thole LM; Tizian C; Hölsken O; Diefenbach A; Schrezenmeier H; Jahrsdörfer B; Zemojtel T; Jechow K; Conrad C; Lukassen S; Stauch D; Lachmann N; Choi M; Halleck F; Kotsch K
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34101623
[TBL] [Abstract][Full Text] [Related]
32. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
[TBL] [Abstract][Full Text] [Related]
33. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
Front Immunol; 2022; 13():908108. PubMed ID: 35911701
[TBL] [Abstract][Full Text] [Related]
34. IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination.
Van Elslande J; Weemaes M; Godderis L; Van Pottelbergh G; Bossuyt X; Vermeersch P
Diagn Microbiol Infect Dis; 2022 Apr; 102(4):115638. PubMed ID: 35104720
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 Immunity in the Cohort of IRCCS San Raffaele Hospital Employees after BNT162b2 Vaccination: A Retrospective Observational Study.
Stocchi M; Melodia P; Lucini A; De Lorenzo R; Pozzi C; Rovere-Querini P; Odone A; Renzi C; Signorelli C
Ann Ig; 2024; 36(4):432-445. PubMed ID: 38386027
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.
Miyakawa K; Kato H; Ohtake N; Jeremiah SS; Ryo A
J Infect Dis; 2023 Jan; 227(2):221-225. PubMed ID: 35978486
[TBL] [Abstract][Full Text] [Related]
37. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
38. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():896151. PubMed ID: 35844588
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
40. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
